UNSPSC 51131801: Fibrinogen

This classification denotes a plasma glycoprotein clotted by thrombin composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds, and which is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N94833051K.

European Medicines Agency schedules Fibrinogen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12502MIG. The term FIBRINOGEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19.) Fibrinogen bears US NLM identifiers UMLS ID C0016006 and NCI Concept Code C25736.

UNSPSC 51131801 Fibrinogen, a Commodity code, covers blood-clotting agents and blood products used in medical and emergency response contexts. Recent state and local procurement activity under this code shows minimal direct solicitation; the single recent opportunity tagged to the code—Sourcewell RFP #061626 for Law Enforcement Equipment, posted May 12, 2026 with a June 16, 2026 response deadline—does not reflect fibrinogen procurement itself but rather a broader cooperative purchasing vehicle for law enforcement equipment offered to thousands of public entities across the United States and Canada. Sourcewell, a Minnesota local government unit and service cooperative, is the issuing body, administering the cooperative contract on behalf of participating Washington counties (Franklin, Grant, Grays Harbor, Chelan, and Yakima) and numerous other jurisdictions and public entities. The mismatch between the code's nominal scope and the actual solicitation suggests that fibrinogen does not see regular direct solicitation in state and local procurement markets captured in recent postings, or that the code has been applied to the opportunity in error.

Geographic activity under the code is not clearly defined; the single recent opportunity is administered from Minnesota and encompasses Washington state counties, but the cooperative structure extends to participating entities across the United States and Canada. No separate state or local opportunities specifically naming fibrinogen procurement, medical supply contracts, blood-product acquisitions, or related clinical procurement have appeared in recent postings. Firms evaluating fibrinogen sales to state and local government should monitor cooperative purchasing frameworks—particularly those managed by Sourcewell or similar multi-jurisdictional vehicles—but should not rely on this code as a signal of current demand.